Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oncology company Incanthera narrowed annual losses on lower costs.
For the year ended 31 March, pre-tax losses narrowed to £1.2m from £2m on-year as costs operating costs fell to £933K from £1,636K on-year.
Looking ahead, the company said it would further develop its skin cancer asset, Sol, which had 'received very positive support from investors during our fundraising, and we are already making great progress towards its commercialisation.'